about kinex
Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases.
Our Company >>clinical trials
Kinex plans to enter multiple Phase 2 studies with KX01 in 2012. Clinical studies will include castrate-resistant prostate cancer (CRPC), leukemia (CML), ovarian cancer and triple-negative breast cancer (TNB).
Clinical Trials >>News/Events
Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
Monday, December 19th, 2011
Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement from Hanmi Pharmaceuticals granting Kinex Pharmaceuticals
KX2-391 has Entered into Phase 1b Clinical Trial for AML
Friday, December 9th, 2011
Kinex Pharmaceuticals has announced that its oncology drug, KX2-391, has entered a clinical trial entitled “A Phase Ib Rising Multiple-Dose Clinical Study


